H.C. Wainwright raised the firm’s price target on Femasys to $12 from $10 and keeps a Buy rating on the shares following the Q4 report. The analyst says the FemaSeed pivotal data announced recently could boost the initial launch expected in the first half of 2024. The firm sees potential for high uptake following the positive pivotal data results, saying they show validation of higher pregnancy rates that could be obtained with FemaSeed relative to IUI, which is standard first-line treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
- Femasys participates in a conference call with JonesResearch
- Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
- Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
- Femasys announces topline data from trial of FemaSeed for infertility